Screener
Exelixis EXEL License revenues — Total revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Exelixis in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Exelixis’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:13 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q3 2026
- Accession
- 0000939767-26-000098
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Gross product revenues | $812,782 | $745,280 | $1,608,136 | $1,466,991 |
| Discounts and allowances | (239,757) | (225,266) | (480,134) | (433,694) |
| Net product revenues | 573,025 | 520,014 | 1,128,002 | 1,033,297 |
| Collaboration revenues: | ||||
| License revenues | 59,810 | 49,301 | 116,758 | 91,781 |
| Collaboration services revenues | (4,145) | (1,054) | (5,258) | (1,370) |
| Collaboration revenues | 55,665 | 48,247 | 111,500 | 90,411 |
| Total revenues | $628,690 | $568,261 | $1,239,502 | $1,123,708 |
Item 1. Financial Statements.
FAQ
- What is Exelixis's license revenues — total revenues?
- Exelixis (EXEL) reported license revenues — total revenues of $59.81M in Q2 2026.
- How has Exelixis's license revenues — total revenues changed year-over-year?
- Exelixis's license revenues — total revenues increased by 21.3% year-over-year, from $49.3M to $59.81M.
- What is the long-term trend for Exelixis's license revenues — total revenues?
- Over 4 years (2021 to 2025), Exelixis's license revenues — total revenues has grown at a -3.8% compound annual growth rate (CAGR), from $249.96M to $214.38M.
- What does license revenues — total revenues mean?
- This metric represents the aggregate revenue recognized from licensing agreements, including royalties, milestone payments, and other contract-based fees related to intellectual property. It reflects the company's ability to monetize its drug discovery and development pipeline through partnerships with other pharmaceutical entities. This revenue stream is a critical component of the company's business model for leveraging external commercialization capabilities.
Ask your AI about Exelixis's license revenues — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude